KSHV ORF45 inhibitors are a class of chemical compounds designed to specifically target and inhibit the function of ORF45, a key viral protein expressed by Kaposi's sarcoma-associated herpesvirus (KSHV). ORF45 is an immediate-early protein that plays a critical role in the viral lytic cycle by regulating the activation of signaling pathways and modulating host cell responses. One of the main functions of ORF45 is to interact with and activate the host's p90 ribosomal S6 kinase (RSK), enhancing protein synthesis and viral replication. ORF45 also interferes with the host's immune response by inhibiting interferon production and other antiviral mechanisms. By inhibiting ORF45, researchers can disrupt these processes, leading to a better understanding of viral propagation and immune evasion mechanisms.
Chemically, KSHV ORF45 inhibitors are designed to block the protein's interactions with host cell signaling molecules or to disrupt its ability to modulate cellular responses. These inhibitors may target the specific domains of ORF45 responsible for binding to RSK or other host proteins, preventing the activation of downstream signaling pathways that promote viral replication. Alternatively, the inhibitors might interfere with ORF45's ability to suppress the host immune response by blocking its interaction with key regulatory proteins involved in antiviral defense. The development of these inhibitors involves techniques such as high-throughput screening, molecular modeling, and structure-activity relationship (SAR) studies to identify compounds that selectively inhibit ORF45 without affecting other cellular processes. By inhibiting ORF45, researchers gain insights into how KSHV manipulates host cell signaling and immune responses, providing a deeper understanding of the molecular interactions that facilitate the virus's lifecycle.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $246.00 $490.00 $536.00 | 16 | |
These inhibitors can modulate the JAK/STAT pathway, potentially impacting ORF 45's role in immune response modulation. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
By inhibiting NF-κB, a pathway often exploited by viruses for immune evasion, these compounds can indirectly affect ORF 45. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Targeting the PI3K/Akt pathway, which is involved in cell survival and viral replication, might influence ORF 45 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
By inhibiting mTOR, these compounds can affect cell growth and viral replication, potentially impacting ORF 45. | ||||||
IKK 16 | 1186195-62-9 | sc-204009 sc-204009A | 10 mg 50 mg | $219.00 $924.00 | 2 | |
Targeting IκB kinase, these inhibitors can modulate NF-κB activation, potentially affecting ORF 45's role in immune evasion. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $66.00 $278.00 | 6 | |
As modulators of Toll-like receptor signaling, these agents might influence immune responses relevant to ORF 45's function. | ||||||
BX 795 | 702675-74-9 | sc-281689 sc-281689A sc-281689C sc-281689B sc-281689D sc-281689E | 2 mg 5 mg 10 mg 25 mg 50 mg 100 mg | $219.00 $273.00 $331.00 $495.00 $882.00 $1489.00 | 5 | |
Inhibiting Interferon Regulatory Factors could impact the immune modulation associated with ORF 45. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
By modulating the MAPK pathway, these inhibitors could indirectly influence ORF 45's activities in the host cell. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
These inhibitors can impact protein degradation pathways, potentially affecting ORF 45 stability and function. | ||||||
Autophagy Inhibitor, 3-MA | 5142-23-4 | sc-205596 sc-205596A | 50 mg 500 mg | $56.00 $256.00 | 113 | |
Targeting autophagy, a process sometimes hijacked by viruses, could indirectly influence ORF 45. | ||||||